[Belgium, Mol], June 13th, 2026
PanTera wishes to issue a clarification following an article published on June 12, 2026 by Mergermarket, reporting on an alleged intention by Pantera to proceed with a divestiture or a capital raise.
PanTera wants to explicitly confirm that no such decision has been made and wishes to point out that any significant strategic decision regarding shareholding would be the subject of an appropriate official communication in due course. PanTera today has not decided on a strategy regarding the further development of the company and keeps all options open.
PanTera remains fully focused on developing its business as a leading producer of actinium 225, in support of the development of targeted alpha therapies for the benefit of patients.